Ocular Therapeutix, Inc (OCUL): Cost of Revenue
$6.57M
Year ended 2025-12-31
$6.71M
Trailing 12 months to 2026-06-30
+13.1%
3-year compound annual growth
+25.8%
5-year compound annual growth
+35.3%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.57M | +16.9% | 2026-02-05, From 2025-01-01 |
| 2024-12-31 | $5.63M | +6.5% | 2026-02-05, From 2024-01-01 |
| 2023-12-31 | $5.28M | +16.3% | 2026-02-05, From 2023-01-01 |
| 2022-12-31 | $4.54M | +3.0% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $4.41M | +111.5% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $2.08M | -10.4% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $2.33M | +400.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $465.0K | +1.8% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $457.0K | +3.2% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $443.0K | +38.9% | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | $319.0K | +250.5% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $91.0K | n/a | 2017-03-10, From 2014-01-01 |
| No annual figure between 2012-12-31 and 2014-12-31. | |||
| 2012-12-31 | $7.0K | n/a | 2015-03-20, From 2012-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $6.57M | +16.9% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $6.34M | +52.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $274.0K | -55.5% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $0 | -100.0% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $20.75M | +1.0% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $18.55M | +3.8% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $6.67M | +1.2% |
| Journey Medical Corp (DERM) | 2025-12-31 | $20.92M | +0.2% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $43.07M | -11.7% |
Compare OCUL, AGIO, LXRX, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗